Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate

Philippos Apolinario Costaa Department of Medicine, Division of Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, USA

https://orcid.org/0000-0001-9681-0515

Andrea Patricia Espejo-Freireb Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

Kenneth Chen Fanc Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA

Thomas Arno Albinic Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA

Georgios Pongasb Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence[email protected]

Click to increase image sizeClick to decrease image size

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate

Information for

Open access

Opportunities

Help and information

Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature